Showing results (11-20 of 14) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Leukemia & Lymphoma|October 28, 2020
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studiesXavier Leleu, Meral Beksac, Takaaki Chou, et al.Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.British Journal of Haematology|February 18, 2017
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE studyMeletios A Dimopoulos, A Keith Stewart, Tamás Masszi, et al.Blood|July 22, 2016
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myelomaHervé Avet-Loiseau, Rafael Fonseca, David Siegel, et al.Pageof 2